AH020 - Why NADAC is a "Ray of Sunshine," with AJ Loiacono and Antonio Ciaccia

What do you get when schedules line up and AJ Loiacono and Antonio Ciaccia are the guests on a podcast? An episode you must listen to if your work or interests are in any way centered on drug prices. NADAC - national average drug acquisition cost - was the focus of our discussion on this episode of the Astonishing Healthcare podcast. Recent methodology changes and a new survey participant have combined to drive meaningful deflation in generic drug prices. AJ and Antonio dive into why this is significant and other factors stakeholders should consider. NADAC serves as a crucial price benchmark, providing visibility and some level of understanding - a "source of truth" - of drug pricing in the United States. Average wholesale price (AWP) and other indexes fail to reflect actual acquisition cost/supply chain economics but have prevailed for years. Is it the pharmacy benefits managers (PBMs)? Is it the wholesalers? At Capital Rx, we have always preferred to leverage NADAC whenever possible despite its imperfections. Nothing is perfect in the pharmaceutical supply chain regarding drug pricing, and NADAC remains the best, most reliable option. Tune in to discover what's happened and what to watch for next! Related Content What is NADAC & How Does It Differ From AWP? (https://www.cap-rx.com/insights/what-...) Why Use NADAC-Based Pricing Over AWP (https://www.cap-rx.com/insights/why-u...) Medicaid.gov - Drug Pricing (https://www.medicaid.gov/medicaid/pre...) (where NADAC lives) Please visit Capital Rx Insights (https://www.cap-rx.com/insights) for more information, including this episode's transcript, AND we'll add links to any new studies or documents that may interest you if you're a student of drug prices or a fan of NADAC.